Sun Pharma has also guided for an investment of $100 million in new launches. During the year, besides new launches, Sun Pharma will also unveil important clinical data on its new chemical entity pipeline (Vibozilimod, Ilumya in psoriatic arthritis) and the clinical data should be important as it would shape sentiment around medium to long term growth.